To address this issue, this study employed the rat model of puromycin aminonucleoside (PAN) nephrosis, a well-characterized model of nephrotic glomerulopathy, and tested the effectiveness of synthetic melanocortin peptidomimetics with MC5R activating activities, including the pan MCR agonist [Nle4, DPhe7]-α-melanocyte-stimulating hormone (NDP-MSH) and a novel highly selective MC5R agonist (MC5R-A). The gene discussed is MC5R; the disease is nephrosis.